Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is well-positioned in the medical technology industry with a strong portfolio of products that cater to various medical needs, making it a reliable source of revenue and cash flow. Strength in its Extremities and hips and knees segments, as well as the growth of its new products, have contributed to its consistent organic revenue growth. The company's focus on increasing free cash flow conversion and improving operational leverage, along with its attractive entry point and steady performance, make it a promising investment opportunity.

Bears say

Enovis is facing several challenges including slower-than-expected top-line growth, higher contributions from its mature and less attractive P&R segment, and continued tariff pressures. These factors could lead to slower revenue growth, margin compression, and potential difficulties in integrating recent M&A activities. As a result, we believe that Enovis's stock may underperform its peers and face downside risks.

Enovis Corp (ENOV) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.